1
|
Van Cutsem E, Sagaert X, Topal B,
Haustermans K and Prenen H: Gastric cancer. Lancet. 388:2654–2664.
2016. View Article : Google Scholar : PubMed/NCBI
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
3
|
Cepeda V, Fuertes MA, Castilla J, Alonso
C, Quevedo C and Pérez JM: Biochemical mechanisms of cisplatin
cytotoxicity. Anticancer Agents Med Chem. 7:3–18. 2007. View Article : Google Scholar : PubMed/NCBI
|
4
|
Shi WJ and Gao JB: Molecular mechanisms of
chemoresistance in gastric cancer. World J Gastrointest Oncol.
8:673–681. 2016. View Article : Google Scholar : PubMed/NCBI
|
5
|
Liu H, Li N, Yao L, Jiang L, Bao G, Li J,
Ma Q and Liu Z: Prediction of doxorubicin sensitivity in gastric
cancers based on a set of novel markers. Oncol Rep. 20:963–969.
2008.PubMed/NCBI
|
6
|
Tacar O, Sriamornsak P and Dass CR:
Doxorubicin: An update on anticancer molecular action, toxicity and
novel drug delivery systems. J Pharm Pharmacol. 65:157–170. 2013.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Eker B, Meissner R, Bertsch A, Mehta K and
Renaud P: Label-free recognition of drug resistance via
impedimetric screening of breast cancer cells. PLoS One.
8:e574232013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Vinod BS, Maliekal TT and Anto RJ:
Phytochemicals as chemosensitizers: From molecular mechanism to
clinical significance. Antioxid Redox Signal. 18:1307–1348. 2013.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Chen ZF and Liang H: Progresses in TCM
metal-based antitumour agents. Anticancer Agents Med Chem.
10:412–423. 2010. View Article : Google Scholar : PubMed/NCBI
|
10
|
He Y, Ding J, Lin Y, Li J, Shi Y, Wang J,
Zhu Y, Wang K and Hu X: Gambogenic acid alters chemosensitivity of
breast cancer cells to Adriamycin. BMC Complement Altern Med.
15:1812015. View Article : Google Scholar : PubMed/NCBI
|
11
|
Choi HS, Cho SG, Kim MK, Kim MS, Moon SH,
Kim IH and Ko SG: Decursin in Angelica gigas Nakai (AGN) enhances
doxorubicin chemosensitivity in NCI/ADR-RES ovarian cancer cells
via inhibition of P-glycoprotein expression. Phytother Res.
30:2020–2026. 2016. View
Article : Google Scholar : PubMed/NCBI
|
12
|
Wang D, Wang S, Chen X, Xu X, Zhu J, Nie L
and Long X: Antitussive, expectorant and anti-inflammatory
activities of four alkaloids isolated from Bulbus of Fritillaria
wabuensis. J Ethnopharmacol. 139:189–193. 2012. View Article : Google Scholar : PubMed/NCBI
|
13
|
Wang DD, Feng Y, Li Z, Zhang L, Wang S,
Zhang CY, Wang XX and Liu ZY: In vitro and in vivo antitumor
activity of Bulbus Fritillariae Cirrhosae and preliminary
investigation of its mechanism. Nutr Cancer. 66:441–452. 2014.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Lyu Q, Tou F, Su H, Wu X, Chen X and Zheng
Z: The natural product peiminine represses colorectal carcinoma
tumor growth by inducing autophagic cell death. Biochem Biophys Res
Commun. 462:38–45. 2015. View Article : Google Scholar : PubMed/NCBI
|
15
|
Wang H, Cai S, Ernstberger A, Bailey BJ,
Wang MZ, Cai W, Goebel WS, Czader MB, Crean C, Suvannasankha A, et
al: Temozolomide-mediated DNA methylation in human myeloid
precursor cells: Differential involvement of intrinsic and
extrinsic apoptotic pathways. Clin Cancer Res. 19:2699–2709. 2013.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Zhu Y, Yu F, Jiao Y, Feng J, Tang W, Yao
H, Gong C, Chen J, Su F, Zhang Y and Song E: Reduced miR-128 in
breast tumor-initiating cells induces chemotherapeutic resistance
via Bmi-1 and ABCC5. Clin Cancer Res. 17:7105–7115. 2011.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Wang C, Huo X, Wang L, Meng Q, Liu Z, Liu
Q, Sun H, Sun P, Peng J and Liu K: Dioscin strengthens the
efficiency of adriamycin in MCF-7 and MCF-7/ADR cells through
autophagy induction: More than just down-regulation of MDR1. Sci
Rep. 6:284032016. View Article : Google Scholar : PubMed/NCBI
|
18
|
Li SZ, Qiao SF, Zhang JH and Li K:
Quercetin increase the chemosensitivity of breast cancer cells to
doxorubicin via PTEN/Akt pathway. Anticancer Agents Med Chem.
15:1185–1189. 2015. View Article : Google Scholar : PubMed/NCBI
|
19
|
Wang J, Zhang G, Dai C, Gao X, Wu J, Shen
L, Chen Z and Liu P: Cryptotanshinone potentiates the antitumor
effects of doxorubicin on gastric cancer cells via inhibition of
STAT3 activity. J Int Med Res. 45:220–230. 2017. View Article : Google Scholar : PubMed/NCBI
|
20
|
Xu YH, Richert N, Ito S, Merlino GT and
Pastan I: Characterization of epidermal growth factor receptor gene
expression in malignant and normal human cell lines. Proc Natl Acad
Sci USA. 81:pp. 7308–7312. 1984; View Article : Google Scholar : PubMed/NCBI
|
21
|
Ichikawa W, Kurahashi I, Sakuramoto S,
Katai H, Sano T, Imamura H and Sasako M; ACTS-GC Group, : Impact of
expression of human epidermal growth factor receptors EGFR and
ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res.
18:5992–6000. 2012. View Article : Google Scholar : PubMed/NCBI
|
22
|
Galizia G, Lieto E, Orditura M, Castellano
P, Mura AL, Imperatore V, Pinto M, Zamboli A, De Vita F and
Ferraraccio F: Epidermal growth factor receptor (EGFR) expression
is associated with a worse prognosis in gastric cancer patients
undergoing curative surgery. World J Surg. 31:1458–1468. 2007.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Lieto E, Ferraraccio F, Orditura M,
Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F and Galizia G:
Expression of vascular endothelial growth factor (VEGF) and
epidermal growth factor receptor (EGFR) is an independent
prognostic indicator of worse outcome in gastric cancer patients.
Ann Surg Oncol. 15:69–79. 2008. View Article : Google Scholar : PubMed/NCBI
|
24
|
Wang J, Yang S, Cai X, Dong J, Chen Z,
Wang R, Zhang S, Cao H, Lu D, Jin T, et al: Berberine inhibits EGFR
signaling and enhances the antitumor effects of EGFR inhibitors in
gastric cancer. Oncotarget. 7:76076–76086. 2016.PubMed/NCBI
|
25
|
Mu L, Wang T, Chen Y, Tang X, Yuan Y and
Zhao Y: β-Elemene enhances the efficacy of gefitinib on
glioblastoma multiforme cells through the inhibition of the EGFR
signaling pathway. Int J Oncol. 49:1427–1436. 2016. View Article : Google Scholar : PubMed/NCBI
|
26
|
Proto C, Imbimbo M, Gallucci R, Brissa A,
Signorelli D, Vitali M, Macerelli M, Corrao G, Ganzinelli M, Greco
FG, et al: Epidermal growth factor receptor tyrosine kinase
inhibitors for the treatment of central nervous system metastases
from non-small cell lung cancer: The present and the future. Transl
Lung Cancer Res. 5:563–578. 2016. View Article : Google Scholar : PubMed/NCBI
|
27
|
Brand TM, Iida M and Wheeler DL: Molecular
mechanisms of resistance to the EGFR monoclonal antibody cetuximab.
Cancer Biol Ther. 11:777–792. 2011. View Article : Google Scholar : PubMed/NCBI
|
28
|
Ayyappan S, Prabhakar D and Sharma N:
Epidermal growth factor receptor (EGFR)-targeted therapies in
esophagogastric cancer. Anticancer Res. 33:4139–4155.
2013.PubMed/NCBI
|
29
|
Leung EL, Tam IY, Tin VP, Chua DT, Sihoe
AD, Cheng LC, Ho JC, Chung LP and Wong MP: SRC promotes survival
and invasion of lung cancers with epidermal growth factor receptor
abnormalities and is a potential candidate for molecular-targeted
therapy. Mol Cancer Res. 7:923–932. 2009. View Article : Google Scholar : PubMed/NCBI
|
30
|
Schwock J, Dhani N and Hedley DW:
Targeting focal adhesion kinase signaling in tumor growth and
metastasis. Expert Opin Ther Targets. 14:77–94. 2010. View Article : Google Scholar : PubMed/NCBI
|
31
|
Schlaepfer DD, Mitra SK and Ilic D:
Control of motile and invasive cell phenotypes by focal adhesion
kinase. Biochim Biophys Acta. 1692:77–102. 2004. View Article : Google Scholar : PubMed/NCBI
|
32
|
Hao Z, Qian J and Yang J: Shikonin induces
apoptosis and inhibits migration of ovarian carcinoma cells by
inhibiting the phosphorylation of Src and FAK. Oncol Lett.
9:629–633. 2015. View Article : Google Scholar : PubMed/NCBI
|
33
|
Heffler M, Golubovskaya VM, Dunn KM and
Cance W: Focal adhesion kinase autophosphorylation inhibition
decreases colon cancer cell growth and enhances the efficacy of
chemotherapy. Cancer Biol Ther. 14:761–772. 2013. View Article : Google Scholar : PubMed/NCBI
|
34
|
Ren K, Lu X, Yao N, Chen Y, Yang A, Chen
H, Zhang J, Wu S, Shi X, Wang C, et al: Focal adhesion kinase
overexpression and its impact on human osteosarcoma. Oncotarget.
6:31085–31103. 2015. View Article : Google Scholar : PubMed/NCBI
|
35
|
Lai IR, Chu PY, Lin HS, Liou JY, Jan YJ,
Lee JC and Shen TL: Phosphorylation of focal adhesion kinase at
Tyr397 in gastric carcinomas and its clinical significance. Am J
Pathol. 177:1629–1637. 2010. View Article : Google Scholar : PubMed/NCBI
|